Skip to main content

Drug Interactions between azathioprine and febuxostat

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

azaTHIOprine febuxostat

Applies to: azathioprine and febuxostat

CONTRAINDICATED: Coadministration with febuxostat may significantly increase the plasma concentrations of xanthine oxidase substrates such as azathioprine, mercaptopurine, and theophylline. Toxicity may result. The proposed mechanism is inhibition of xanthine oxidase by febuxostat. Although drug interaction studies have not been conducted with febuxostat and xanthine oxidase substrates, the interaction has been reported with allopurinol, another xanthine oxidase inhibitor. Severe bone marrow suppression and other toxicities have been associated with concomitant use of allopurinol and mercaptopurine (6-MP) or azathioprine. Increased theophylline concentrations have also been reported during coadministration with allopurinol at dosages of 600 mg/day or greater.

MANAGEMENT: The use of febuxostat in patients treated with azathioprine, mercaptopurine, or theophylline is considered contraindicated.

References (1)
  1. (2009) "Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer